Ready to Use Intravenous Ibuprofen in Adult and Paediatric Multimodal Perioperative Analgesia: European Clinical Expert Opinion Authors: Anna Camporesi, Marc J Coppens, Tom De Leeuw, Gabriele Finco, Henry Jaimes, Svetlana Vassileva Kotzeva, Rosalia Navarro Pérez, Andy Yuet Meng Ng, Robert Sümpelmann Published: 2026 ABSTRACT AbstractDespite the increasing availability of IV analgesics, perioperative pain management remains a challenge, especially in pediatric care where most IV NSAIDs do not have labelled indications. NSAIDs are consistently identified as essential for multimodal analgesia protocols. This document summarizes key discussions of a 2023 Medical Advisory Board Meeting (Frankfurt, Germany) on Ready-to-use (RTU) IV Ibuprofen, complemented by follow-up clinician questionnaires describing institutional clinical protocols, perceived benefits and safety considerations. Ready-to-use IV ibuprofen has become available in Europe in the last few years, prior to its worldwide launching. This paper aims to provide valuable insights and serve as a reference point for the introduction of this new formulation by colleagues in other countries. Ibuprofen inhibits COX-1 and COX-2 enzymes with a favorable COX-1/COX-2 ratio, reducing side effects. Its pharmacokinetics are consistent across age groups, and it is considered safe for pediatric and elderly populations. Experts reported broad adoption of RTU IV Ibuprofen across multiple surgical settings, with consistent analgesic efficacy and evident opioid-sparing effects. Protocols referred by the authors included mainly preemptive analgesia and multimodal strategies tailored to patient needs. Reported advantages for IV Ibuprofen included rapid onset of action, accurate dosing, faster recovery, and workflow benefits from a premixed preparation, making it suitable for hospitalized patients. Contraindications include allergies, active bleeding, and severe renal failure. Board members reported no increased bleeding risk in their experience with IV Ibuprofen.Keywords: multimodal analgesia, opioid-sparing benefit, RTU IV ibuprofen, perioperative pain management, pediatric analgesia, WHO list of essential medicines Introduction Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), traditionally administered orally, topically, and rectally, has long been recognized for its analgesic, antipyretic, and anti-inflammatory properties. Ibuprofen is probably the most widely used NSAIDs globally, both for adults and children and the only one of its class listed by WHO in both their adults and children “List of Essential Medicines”, when it comes to pain treatment. The introduction of ready-to-use (RTU) intravenous (IV) Ibuprofen offers interesting advantages in acute pain management, particularly in clinical settings where accurate rapid onset of action and ease of administration are crucial. This paper presents the proceedings and recommendations from an advisory board detailing European anaesthesiologists’ clinical practices, and the benefits and precautions of using IV Ibuprofen. It introduces also B. Braun’s RTU-IV Ibuprofen (B. Braun Melsungen AG, Germany), explores the clinical experience with RTU-IV Ibuprofen in Europe, highlights its advantages and applications, and its role in perioperative pain management. The main objective is to provide first-hand trustworthy reference information to encourage clinical practice update to facilitate the implementation of perioperative multimodal analgesia protocols, focusing on the NSAIDs and particularly on IV Ibuprofen. The Advisory Board The recent availability in Europe of RTU-IV Ibuprofen encouraged the creation in 2023 of a dynamic advisory board composed of European anaesthesiologists to discuss about pain management in adults and children. The advisory board was initiated by Spanish and German clinicians who were early adopters of RTU IV ibuprofen. Clinicians from other countries with substantial experience in multimodal analgesia were invited. Prior use of RTU IV ibuprofen was not required. In total, eight anaesthesiologists from Belgium, Italy, the Netherlands, Spain, and the United Kingdom participated actively. Most had more than 20 years of clinical practice, and seven of the eight had used RTU IV ibuprofen for more than two years. Information was collected through face-to-face meetings, teleconferences, and questionnaires. Data were primarily qualitative and covered participants’ prior experience with perioperative pain management; main surgical procedures managed (patient populations and case frequency); preferred analgesic regimens; perceived advantages and potential disadvantages of different options; how risk factors influenced analgesic choice; adverse events; and perceived clinical benefits. All responses were entered into a single database. Similitudes and differences in clinical practices were identified and qualitatively presented. Discrepancies and missing information were addressed using standard data-validation procedures. No formal statistical analyses were planned or performed. The Advisory Board’s interactions focused on acute pain management strategies including the use of IV Ibuprofen and its opioid-sparing effects. Discussions also took place about IV Ibuprofen’s safety in various patient groups, particularly paediatrics, elderly adults, patients with moderate renal impairment, and those undergoing surgeries with a high bleeding risk. Acute Pain Management in Europe, Still a Challenge Pain arises from actual or potential tissue damage and is a very subjective experience. Acute pain is a response to adverse factors associated with surgery, trauma or illness, and it is typically self-limited. However, inadequately controlled acute pain can be a cause in the development of chronic pain, extended hospital stay, readmission and patient dissatisfaction. In hospital settings, effective pain management is a cornerstone of patient care. Patient comfort and symptoms resolution play a key role in recovery and length of stay.1 Whilst pain management is a necessity, oligoanalgesia remains a reality for many patients. Causes for this include: poor pain assessment, reduced patient’s capability to report pain, lack of pain management protocols or adherence to them, resistance to use some analgesics, and analgesics availability.2 A wide range of intravenous analgesics are currently available for use in hospitalised patients including both opioids and non-opioid; however, differences in their availability exist across countries and hospitals in Europe. Oral analgesics have been used for many years to treat pain and fever in the hospital setting, but a large percentage of these patients are often unable to take oral medications due to intubation or unconsciousness. These issues can make the intravenous route a more suitable option for hospitalised patients.3 Also, IV administration has the advantage of accurate blood concentrations and rapid onset of effect, but it requires an IV access and trained staff to perform it. Traditionally IV opioids have been widely used, but they come with significant drawbacks.4 Opioid-induced respiratory depression can lead to hypoxaemia, hypercapnia, cardiorespiratory arrest, increased morbidity and mortality, prolonged hospital stay and higher healthcare costs. Opioids suppress both ventilatory and pharyngeal neuromotor drive, reducing airway patency and increasing the risk of adverse respiratory effects. Additionally, high-certainty evidence indicates that opioid increases the risk of nausea, vomiting, constipation, dizziness and drowsiness.5 Evidence also suggests that opioid prescribing at surgical discharge does not reduce pain intensity but does increase adverse events.6 In Europe, a range of national or regional guidelines for multimodal pain management are in place with evidence suggesting that when correctly implemented they promote improved outcomes, increased analgesia administration and greater patient satisfaction.2 Nevertheless, their degree of implementation is variable across countries. Likewise, the management of patients also differs. There is no single standard of care for the management of pain. As every patient experiences pain differently, changing practices, attitudes and behaviours in pain management may be challenging. As a result, interventions and improvements should be developed with the individual patient requirements in mind.7 National and international guidelines recommend Ibuprofen, among others, as effective and safe therapeutic options for acute moderate pain management, eg The National Institute for Health and Care Excellence (NICE),8 The European Society for Emergency Medicine (EUSEM),7 The Association of Anaesthetists and the British Pain Society,9 World Health Organisation (WHO) 2025,10 The European Society for Paediatric Anaesthesiology (ESPA) Pain Management Initiative.11 The European Medicines Agency (EMA), and Countries healthcare authorities (eg. Agenzia Italiana del Farmaco (AIFA), Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Belgium’s Federal Agency for Medicines and Health Products (FAMHP), UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), Zentralstelle del Länder für Gesundheistsschutz bei Arzneimitteln Medizinproduckten (ZLG), Inspectie voor de Gezondheidszorg (IGZ)), also provide recommendations and guidance particularly based on safety issues. Ibuprofen Pharmacology Ibuprofen [(±)-2-(−4-Isobutylphenyl) propionic acid], is a nonsteroidal anti-inflammatory agent. It exerts its therapeutic effect when the inactive R(-) isomer is unidirectionally converted into the active S(+) isomer. Its main action is due to the blockage of prostaglandin synthesis through the non-selective inhibition of the cyclooxygenase (COX) enzymes, meaning that both isoforms, COX-1 and COX-2, are inhibited. While it has been generally reported that the anti-inflammatory effect is mediated through COX-2 inhibition, and that gastric, renal, haematological and gastrointestinal adverse effects are related to COX-1 inhibition, the close interrelation between both enzymes makes their biological activity more complex. Among COX inhibitors, Ibuprofen has one of the lowest COX-1/COX-2 inhibition ratios (0.5), meaning that action on COX-2 is twice higher than on COX-1. This inhibitory balance, and the reversible action of Ibuprofen towards COX isoforms which allows full recovery of enzymatic activity after Ibuprofen’s metabolism and elimination, effectively reduce the risk of side effects.12–14 It has long been known that Ibuprofen and Ketoprofen may have similar anti-inflammatory effect; however, Ketoprofen shows a significantly higher effect (4 to 20 times more than Ibuprofen) on platelets aggregation, which could clinically represent a bigger bleeding risk.15 Ibuprofen is mostly excreted by the kidneys after oxidation by cytochromes P450 in the liver. Neither Ibuprofen’s peak plasma concentration nor the extent of Ibuprofen binding to plasma proteins is related to patient’s age or sex. Ibuprofen half-life is relatively short, rarely exceeding 3 hours, thus an Ibuprofen dosage schedule of 3 to 4 times daily is unlikely to cause Ibuprofen accumulation in any individual regardless of age.16 None of the metabolites have any pharmacological effect, nor have been found to be toxic; this means that there is no accumulation of active metabolites. A literature review assessing the pharmacokinetics of NSAIDs in infants showed similar data for children and adults, for both oral and IV routes,17 and a multicentre study found that the short-term safety profile of IV Ibuprofen in paediatric patients 1–6 months of age was comparable to those in children older than 6 months.18 RTU IV Ibuprofen Indications and Target Populations RTU IV Ibuprofen (B. Braun) is an innovative version of a medication that has been widely used in humans for more than 60 years. It is available as a solution for IV infusion in three different strengths: 200 mg, 400 mg, and 600 mg. It should be used only when oral administration is inappropriate, and patients must switch to oral administration as early as this is possible. RTU IV Ibuprofen (200 mg for children and 400 mg for adults) is indicated for the short-term symptomatic treatment of acute/moderate pain and for short-term symptomatic treatment of fever when other administration routes are not possible. RTU IV Ibuprofen 600 mg is recommended particularly in the management of pain. The recommended infusion time is 30 minutes. It is also recommended that the IV route of administration should not be used for more than 3 days. Combination with other NSAIDs or aspirin should be avoided. In the European Union (EU) currently, the recommended dose of IV Ibuprofen in adults is 400 mg every 6–8 hours as required. However, depending on local guidance, the mean daily dose (MDD) varies from 1200 mg to 2400 mg. Also, in the EU, the authorised lower limit age is 6 years. However, based on available evidence, its off-label use to treat younger children has been endorsed by scientific societies (eg the Spanish Society for Paediatric Intensive Care – SECIP), and included in pediatric hospital protocols. When indicated, children weighing 20–29 kg (6–9 years old) should receive 200 mg of Ibuprofen up to 3 times a day, not exceeding an MDD of 600 mg; children weighing 30–39 kg (10–11 years old) should receive 200 mg Ibuprofen up to 4 times a day, not exceeding an MDD of 800 mg; adolescents weighing 40 kg or more (12–17 years old) should receive 200 to 400 mg up to 3 times a day, not exceeding an MDD of 1200 mg. In countries like Croatia, Bulgaria, North Macedonia, Colombia, and Mexico the MDD for adults is 1200 mg, paediatric use is not officially indicated. In Brazil, the MDD authorised for adults is 1200 mg and can be used in children from 12 years with an MDD of 30 mg/kg. To be noticed, IV Ibuprofen is authorised to be used in infants from 3 months of age with a body weight ≥5 kg in countries like Bolivia, Kuwait, Palestine, Singapore, and Malaysia. Two specific IV Ibuprofen presentations, (2 mL ampoules containing 5 mg/mL, available under specific brand names) are authorised by EMA for the treatment of haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. This wide spectrum of authorisations by age only add complexity to the use of Ibuprofen particularly in the paediatric population and by extension to the creation of multimodal analgesia protocols. This information is accurate at the time of writing; however, as certain approvals may still be pending, authorisations may require further update, particularly with respect to age, weight, and dosage. Promoting and Updating Multimodal Analgesia Multimodal analgesia (MMA) combines different analgesic interventions and medications that act at multiple points along the nociceptive pathway to achieve synergistic pain relief. This approach may optimise acute pain control, reduce adverse events, and help prevent progression to chronic pain. MMA has also helped reduce over-reliance on opioids for perioperative analgesia by broadening the use of systemic non-opioid pharmacological options such as nonsteroidal anti-inflammatory drugs (NSAIDs).19 NSAIDs can play an important role in perioperative analgesia because they provide antinociceptive analgesia with anti-inflammatory effects. Clinical evidence indicates that NSAIDs reduce pain and can lower opioid consumption by 20–60%, particularly when used as part of multimodal regimens in combination with other non-opioid analgesics.20,21 Accordingly, NSAIDs are a cornerstone of many multimodal analgesia strategies. Among available options, IV ibuprofen appears to have a more favourable safety profile than some other NSAIDs (eg, diclofenac or ketorolac), particularly with respect to upper gastrointestinal (GI) and cardiovascular adverse events.22,23 Within the broader MMA approach, administering pre-emptive analgesia (PEA) at induction as a single dose of IV ibuprofen has also been associated with significantly reduced postoperative opioid use.21,24 Additionally, a pre-emptive single dose of IV Ibuprofen before laparoscopic cholecystectomy and other operations has been associated with lower postoperative pain levels and 45% less opioid consumption in the first 24 hours after surgery.25 Proceedings from the Advisory Board Board participants had an average 2.8 years of experience with RTU IV Ibuprofen, which coincided with the period IV Ibuprofen had been available in their corresponding institutions. RTU IV Ibuprofen has been and continues to be used in perioperative care of adults and children across a wide range of surgical procedures, including both ambulatory and inpatient procedures. According to board members, analgesia achieved with protocols incorporating IV Ibuprofen was considered as good or very good. In adult patients, board members have used RTU IV Ibuprofen mainly during perioperative pain management of general surgery, orthopaedics/trauma surgery, urological surgery, and gynaecological surgery. One of the board members uses it regularly “for postoperative pain relief after caesarean section”. In children they have used RTU IV Ibuprofen mostly in Ear-Nose-Throat (ENT) surgery, general surgery, orthopaedic surgery and head and neck surgery. Board members use IV Ibuprofen in infants of different ages, but most frequently from 1 to 2 years. One board member informed he was working on a case series with paediatric patients (aged 2–8 years) undergoing tonsillectomy and adenoidectomy (n=140); preliminary results showed that the pain relief obtained with Ibuprofen was superior to the relief obtained with Paracetamol. Advantages of Using RTU IV Ibuprofen Updating institutional protocols to include ready-to-use (RTU) IV ibuprofen can be associated with benefits for both patients and healthcare professionals, including: A clinically meaningful opioid-sparing effect. A clinically meaningful opioid-sparing effect. Effective analgesia across most patient groups and surgical procedures. Effective analgesia across most patient groups and surgical procedures. Potentially earlier recovery and discharge compared with metamizole and some other NSAIDs. Potentially earlier recovery and discharge compared with metamizole and some other NSAIDs. A suitable component of fast-track pathways and Enhanced Recovery After Surgery (ERAS) programmes. A suitable component of fast-track pathways and Enhanced Recovery After Surgery (ERAS) programmes. The ready-to-use formulation eliminates the need for reconstitution, reducing preparation time and the risk of dosing errors—an important consideration in busy clinical environments where timely, accurate administration is essential. The ready-to-use formulation eliminates the need for reconstitution, reducing preparation time and the risk of dosing errors—an important consideration in busy clinical environments where timely, accurate administration is essential. Alignment with broader healthcare priorities, including operational efficiency and patient safety. Alignment with broader healthcare priorities, including operational efficiency and patient safety. In paediatric patients, use of IV ibuprofen has been associated with faster recovery and earlier discharge compared with some other NSAID regimens. In paediatric patients, use of IV ibuprofen has been associated with faster recovery and earlier discharge compared with some other NSAID regimens. Using IV ibuprofen instead of IV diclofenac may reduce the risk of superficial venous thrombosis at the injection site. Using IV ibuprofen instead of IV diclofenac may reduce the risk of superficial venous thrombosis at the injection site. Basic Principles for Implementing MMA Protocols While in general, all MMA protocols share similarities, they are all intrinsically different. As expected, these differences are the result of local guidelines, product availability and practitioners’ own knowledge and experience. While in general, all MMA protocols share similarities, they are all intrinsically different. As expected, these differences are the result of local guidelines, product availability and practitioners’ own knowledge and experience. Some degree of protocol homogenisation for perioperative analgesia is made possible by the introduction of IV Ibuprofen. This is not only because Ibuprofen can be used effectively in adults and children, but also because it is globally safer and has fewer limitations than most of other available NSAIDs. Some degree of protocol homogenisation for perioperative analgesia is made possible by the introduction of IV Ibuprofen. This is not only because Ibuprofen can be used effectively in adults and children, but also because it is globally safer and has fewer limitations than most of other available NSAIDs. IV Ibuprofen may facilitate a seamless institutional rationalisation of NSAIDs for pain management protocols. IV Ibuprofen may facilitate a seamless institutional rationalisation of NSAIDs for pain management protocols. Protocols tend to recommend Pre-emptive Analgesia (PEA) immediately before surgery, with IV Ibuprofen as the recommended analgesic. Protocols tend to recommend Pre-emptive Analgesia (PEA) immediately before surgery, with IV Ibuprofen as the recommended analgesic. In adults the preferred IV Ibuprofen dose for PEA is 600 mg, unless otherwise contraindicated. Although some recommend 400 mg, the final choice (400 mg or 600 mg) is based on patient’s condition. In adults the preferred IV Ibuprofen dose for PEA is 600 mg, unless otherwise contraindicated. Although some recommend 400 mg, the final choice (400 mg or 600 mg) is based on patient’s condition. After major surgery, three doses of IV Ibuprofen are recommended starting 8 hours after the first preemptive dose. After major surgery, three doses of IV Ibuprofen are recommended starting 8 hours after the first preemptive dose. After minor surgery, two doses of IV Ibuprofen are recommended starting 8 hours after the first preemptive dose. After minor surgery, two doses of IV Ibuprofen are recommended starting 8 hours after the first preemptive dose. On the next day after surgery, IV Ibuprofen is administered in hospitalised patients as needed or as a rescue dose. On the next day after surgery, IV Ibuprofen is administered in hospitalised patients as needed or as a rescue dose. Whenever possible, protocol should include other local/regional pharmacological interventions, eg, local anaesthetics. Whenever possible, protocol should include other local/regional pharmacological interventions, eg, local anaesthetics. Protocols should include non-pharmacological interventions for pain management, eg, massages, music. Protocols should include non-pharmacological interventions for pain management, eg, massages, music. IV Ibuprofen can be administered during 24 (some advocate up to 72) hours in the hospitalised patient or until discharge in the ambulatory patient. IV Ibuprofen can be administered during 24 (some advocate up to 72) hours in the hospitalised patient or until discharge in the ambulatory patient. For PEA in children, the IV Ibuprofen dose is 10 mg/kg. Afterward, Ibuprofen is to be administered (8 hours after PEA) 10 mg/kg up to 3 times a day. For PEA in children, the IV Ibuprofen dose is 10 mg/kg. Afterward, Ibuprofen is to be administered (8 hours after PEA) 10 mg/kg up to 3 times a day. In the hospitalised patient, in case of major surgery, opioids can be infused IV for up to 48 hours. In the hospitalised patient, in case of major surgery, opioids can be infused IV for up to 48 hours. Ibuprofen facilitates postsurgical care and could be the first-choice pain medication in hospitalised and ambulatory patients as it allows to keep the same medication with a similar dose and administration schedule while maintaining effective therapeutic plasma levels. Ibuprofen facilitates postsurgical care and could be the first-choice pain medication in hospitalised and ambulatory patients as it allows to keep the same medication with a similar dose and administration schedule while maintaining effective therapeutic plasma levels. Oral Ibuprofen can be combined after surgery with other non-NSAIDs such as Paracetamol when increased analgesia is required. Oral Ibuprofen can be combined after surgery with other non-NSAIDs such as Paracetamol when increased analgesia is required. A summary of steps for MMA implementation is presented in Figure 1. Presents a summarised list of basic steps and workflow required to implement perioperative multimodal analgesia protocols for both adult and paediatric populations. Activities should be flexible enough to be adapted to each individual patient. Key Facts for Successful MMA Implementation Board members emphasize: The importance of developing protocols that allow individualising treatment to ensure appropriate analgesia while guaranteeing patient safety. The importance of developing protocols that allow individualising treatment to ensure appropriate analgesia while guaranteeing patient safety. That both pediatric and geriatric populations have unique analgesic needs. That both pediatric and geriatric populations have unique analgesic needs. That special consideration for pain assessment needs to be given to those who are unable to verbally communicate including the very young and the elderly, and particularly those with cognitive impairment. That special consideration for pain assessment needs to be given to those who are unable to verbally communicate including the very young and the elderly, and particularly those with cognitive impairment. That once analgesia has been provided, regular patient reassessment should be performed to avoid oligoanalgesia and ensure that pain is being successfully managed. That once analgesia has been provided, regular patient reassessment should be performed to avoid oligoanalgesia and ensure that pain is being successfully managed. Special attention should be paid to paediatric patients’ age regarding the use of NSAIDs. Concerning Ibuprofen, age restrictions vary widely globally with countries authorising the use in newborn babies and others restricting its use to patients over 12 years of age. Published evidence favours Ibuprofen safety profile which can be taken as a sign for promoting its use in younger patients.17,18,21,24 The Board clarified that this must not be interpreted as an unrestricted validation to use of NSAIDs in children, rather it has to be seen as an opportunity to take a potentially better therapeutic decision after proper preoperative patient assessment. Special attention should be paid to paediatric patients’ age regarding the use of NSAIDs. Concerning Ibuprofen, age restrictions vary widely globally with countries authorising the use in newborn babies and others restricting its use to patients over 12 years of age. Published evidence favours Ibuprofen safety profile which can be taken as a sign for promoting its use in younger patients.17,18,21,24 The Board clarified that this must not be interpreted as an unrestricted validation to use of NSAIDs in children, rather it has to be seen as an opportunity to take a potentially better therapeutic decision after proper preoperative patient assessment. Precautions of Use in Vulnerable Populations Evidence suggest that Ibuprofen is the safest NSAID for elderly people. A recent study found that IV Ibuprofen used for perioperative pain had a favourable safety profile in older individuals, resulted in a lower incidence of AEs when compared to placebo, and required the use of less opioids postoperatively. The majority of gastrointestinal, renal and cardiac AEs are linked to the chronic use of oral NSAIDs in this vulnerable population.26 Caution is advised in case of renal impairment, gastrointestinal bleeding and cardiovascular events, which are more prevalent in older adults. Board members recommend as a precautionary measure that the maximum dose should not exceed 400 mg in these patients and that doses and administration schedule should be adjusted: dose generally reduced and time between administrations increased. Absolute contraindications include previous allergies to Ibuprofen or to any of its components, severe uncontrolled asthma, active bleeding, active gastric or duodenal ulcer and severe chronic kidney failure. Available scientific evidence indicates that NSAIDs that have long half-life or slow-release formulation and/or are associated with profound and coincident inhibition of both COX isozymes are associated with a greater risk of upper gastrointestinal bleeding/perforation. By its mechanism of action (balanced and reversible COX isoforms inhibition) Ibuprofen, when used for the first time in multimodal analgesia, has an extremely low risk of promoting intra-operatory or post-operatory bleeding. Board members expressed that in their clinical experience IV Ibuprofen has not increased the frequence or the amount of bleeding in adults or children. Beyond this, an appropriate individual preoperative assessment will allow to better define the level of bleeding risk particularly in vulnerable patients and in patients taking NSAIDs for chronic conditions. Increased attention should be paid to patients with coagulation disorders and to patients undergoing surgeries when the predicted blood loss is over 500 mL, in which cases alternatives to NSAIDs should be considered. Adequate hydration of the patient should be maintained to minimise the risk of renal adverse reactions. Limitations This is a work based on published clinical evidence and experts’ opinions, and the collected information is only qualitative; hence, it does not intend to compare products or practices. Recommendations are presented on the same basis. Closing Remarks There have been important advancements in the field of perioperative pain management with the development of multimodal analgesia protocols. There have been important advancements in the field of perioperative pain management with the development of multimodal analgesia protocols. Pain perception is unique to each person; hence, pain management must take into consideration every patient’s specific needs. Pain perception is unique to each person; hence, pain management must take into consideration every patient’s specific needs. Ready-to-use IV ibuprofen is an intravenous NSAID with a very good safety profile that may facilitate the implementation of perioperative pain management protocols for a wide range of patients and surgical indications. Ready-to-use IV ibuprofen is an intravenous NSAID with a very good safety profile that may facilitate the implementation of perioperative pain management protocols for a wide range of patients and surgical indications. European clinical experience suggests that IV ibuprofen can be incorporated into multimodal analgesia protocols in adults and children, including pre-emptive use. This may help reduce opioid requirements and support postoperative recovery. European clinical experience suggests that IV ibuprofen can be incorporated into multimodal analgesia protocols in adults and children, including pre-emptive use. This may help reduce opioid requirements and support postoperative recovery. In paediatric practice, IV ibuprofen may be considered where an intravenous NSAID is indicated; this should be done taking into account local approvals, dosing guidance, and standard NSAID precautions. The RTU IV Ibuprofen formulation may offer practical advantages for preparation and administration in perioperative pathways. Acknowledgments Meeting expenses for participants at the initial advisory board meeting in Frankfurt, Germany, were kindly paid by B. Braun Melsungen AG, Carl-Braun- Straße 1, 34212 Melsungen, Germany. Ethical Considerations This expert-opinion is based on face-to-face discussions and a survey completed by anaesthesiologists regarding their clinical experience in perioperative pain management and, if applicable, on their assessment and use of RTU IV ibuprofen. The Ethical Principles of the Declaration of Helsinki were respected. However, as patients were not enrolled for this work and no identifiable patient-level data were collected, ethics approval and informed consent were not required. Disclosure Dr Marc Coppens reports funds to his institution University Hospital, Ghent, Belgium for advice on IV ibuprofen. Dr Henry Jaimes has received payment from B Braun Medical to support translation and editorial services. Dr Andy Yuet Meng Ng reports personal fees from B. Braun, outside the submitted work. All other authors have no conflicts of interest to declare regarding this work. References